logo
We designed shade out of our cities. We can design it back in

We designed shade out of our cities. We can design it back in

Fast Company4 days ago
As I write these words, a heat wave is sweeping through Europe. Last month, a heat wave swept through the East Coast. Next month, a heat wave might sweep through the Middle East, or South Asia, or North Africa.
As temperatures continue to reach record highs—and climate change increases the likelihood of heat waves—the sun has become foe, and shade has become king. Shade can lower the ambient temperature of the air by as much as 15 to 20 degrees Fahrenheit. It can cool surfaces by as much as 45 degrees.
But where is it?
Ten thousand years ago, more than half of the land on Earth was shaded by tree canopies. Today, after millennia of deforestation, agriculture, and urbanization, that number has dropped to just 30%. The problem is particularly dire in cities: A recent map by UCLA and the nonprofit American Forests revealed staggering 'shade deserts' in almost every major urban region in the U.S. According to journalist and author Sam Bloch, this dearth of shade is by design.
In his new book, simply titled Shade, Bloch argues that the absence of shade from our lives is not an accident. 'Shade has been deliberately designed out of our environments,' he tells me on a recent phone call. 'Those decisions may have made sense in the past, but we are rapidly moving into a new world where sun protection is going to be as important as sun access.'
Shade as old as time
Humans have sought shade for as long as we have lived under the sun. 'Forget palm trees and ponds,' Bloch writes. 'In ancient Mesopotamia, cities were the real oases.' Four thousand years ago, in places where temperatures could soar up to 130 degrees, Sumerians used city walls for shade. They built deep, narrow streets and packed houses close together. Unlike modern cities, which are laid out along the cardinal directions, Sumerians also oriented their cities diagonally, which offered equal amounts of sun and shade on both sides of the street.
In his book, Bloch mentions the work of Mary Shepperson, a U.K. archaeologist who specializes in urban archaeology of the Middle East. After modeling the sun's daily and seasonal paths over Mesopotamian cities, Shepperson found that the orientation of streets, their narrowness, and small protrusions like vertical rooftop parapets and horizontal eaves likely made for pleasant, shaded cities.
The 'wisdom of shade,' as Bloch calls it, was known to the Syrians, Phoenicians, and Persians. Later, it was embraced by the Greeks and Romans, and eventually exported by the Islamic caliphate to modern-day Spain and Portugal. But that is the extent it traveled. Europeans had their own beliefs about what makes a healthy city, and they exported those beliefs to the New World. 'In temperate climates, the sun was their friend, not their enemy,' Bloch writes. 'They had little use for shade.'
How we designed shade out of our cities
If shade is as old as time, so are our preconceptions against it. Over 2,000 years ago, the Greek philosopher Onesicritus taught that shade stunted growth. As Bloch points out, our prejudice against shade even shines through in the language we use: When something is dubious, it's shady. When we feel offended, we take umbrage.
Americans, perhaps more so than others, take particular umbrage at shade. 'We think shade is yucky. It's for damp corners and fetid ponds,' Bloch writes. This goes back to the early colonizing days. When Europeans arrived in modern-day America, they brought with them a 'deep and abiding fear of forests,' which were considered pagan and unholy. In 1771, an English patrician proclaimed 'a garden in a street is not less absurd than a street in a garden.' Or as the author puts it: 'A city dweller who planted trees in their front yard was just another country bumpkin.'
Many factors further contributed to the downfall of shade, but perhaps the most significant of them is our ancestors' fear of tuberculosis. Early research from the 1900s showed that bacteria could be killed with sunlight. This understanding birthed a fixation for sunlight that translated to some of the most famous modernist buildings of the time, including Alvar and Aino Aalto's Paimio Sanatorium in Finland.
In the U.S., urban planners introduced zoning that called for 'setbacks.' They wrote 'solar codes' into urban plans. They widened roads (which also helped cars thrive) and carved out paths for sunlight to reach deep into the streets. 'This fear of tuberculosis has driven so much of our urban design,' Bloch tells me.
The approach trickled down to buildings, as architects clad office buildings and homes with large expanses of glass. Le Corbusier declared glass the foundational material of modernism. Ludwig Mies van der Rohe famously said, 'It's up to the engineers to find some way to stop the heat from coming in or going out,' about his Farnsworth House.
Glass, we know now, is notorious for trapping heat. But it has survived as a material of choice, thanks to another notorious invention: AC. Modern air-conditioning was invented in 1902 by American engineer Willis Carrier, who designed a system to control humidity at a printing plant in Brooklyn, New York. Suddenly, external shading systems like brise-soleils, awnings, sun sails—systems that have been used in European cities for centuries—were dismissed as costly add-ons that could never match the level of comfort provided by cool air being fanned through your house. Case in point: After the Truman administration renovated the White House in the 1950s—installing mechanical cooling in the process—it foolishly took down the stripy summer awnings that once kept it cool.
Air-conditioning revolutionized cooling around the world, but as Bloch writes, 'it came at a cost.' It distanced us from nature and trapped us inside climate-controlled boxes. It lowered our comfort level and our defenses. Even worse: It exacerbated the heat problem it's supposed to solve by sucking the hot air from our houses and expelling it in our cities. According to computer simulations from Paris and Phoenix, the waste heat from AC units makes the surrounding air about 2 to 3 degrees warmer. 'All this happened when we turned our backs on shade,' Bloch writes.
How we can design shade back into our cities
So, how do we learn to love shade again? The good news is that there's no need to reinvent the wheel. In his book, Bloch highlights examples from cities all over the world. In Bologna and Singapore alike, people can walk under miles of covered sidewalks that are carved out of the ground floors of buildings. Italians call them portici (porticoes). In Singapore, they're known as 'five-foot ways.'
In Seville—where seats at the bullring cost two to three times more when they're in the shade—practically all windows are shaded by roller blinds, or persianas de esparto, which are threaded grass curtains that Sevillanos drape over their balconies. Every spring, the Spanish city also installs toldos over streets and plazas. These 'sun sails' have been used for so long (over 500 years) that they have become a proud tool in the city's shade vernacular.
Naturally, every city's 'shade tool kit' will vary based on its climate policy, geographic and socioeconomic conditions, and affinity for design-led solutions. Barcelona has set up 'climate shelters,' while Dallas has been planting thousands of trees. And Los Angeles has been coating its streets and roofs with solar reflective paint.
Since the early 2000s, architects have been pushing for more passive houses. But as Bloch writes, the incentives largely benefit the future occupants, whose energy bills are lowered, not the developers, whose bottom lines remain the same whether or not a building is climate-resilient. This 'split incentive' problem has notably hampered construction and can only be solved if cities implement stronger building codes and grant developers stronger financial incentives. (Building a passive house typically costs around 10% more.)
Perhaps it would help shift our perception of shade if cities classified heat as an environmental hazard, like water or air pollution. The Clean Water Act limited what industries and farms could dump into waterways. The Clean Air Act required power plants and factories to monitor, control, and report their emissions. A similar requirement for heat might help us take more actionable steps toward heat mitigation.
'If we ever agree that heat is a threat to our freedom and happiness, then we might also decide that shade, our defense against it, is an inalienable right,' Bloch writes. (Even if studies have shown the cooling benefits of shade, Bloch says there is no single, widely accepted index to measure shade's thermal impact.)
For Bloch, the problem with shade access isn't necessarily technological but psychological. Some of the experts he interviewed for the book are even calling for a life 'after comfort'—where architecture is made more porous, and where we can learn to live with heat. Studies have found that people who are forced to deal with heat can tolerate it more than those who can escape it.
In the U.S., the ideal indoor temperature ranges between 73 and 78 degrees. In Ouagadougou, Burkina Faso—where AC is virtually nonexistent—studies say that the Burkinabe people's ideal temperature is closer to 86. Similar studies have shown that people in Marrakech, Morocco, are more likely to feel comfortable than people in Phoenix, Arizona, despite a similar climate.
Bloch knows that the cooling effect provided by shade is never going to replace the icy blast of AC. 'Even on a thermodynamic level, it's not doing the same thing,' he tells me. 'But if we can adjust our expectations as to what comfort really is, we might be able to be more tolerant of shade as a viable solution.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Going Nuclear' and ‘Atomic Dreams': Fission's Big Comeback
‘Going Nuclear' and ‘Atomic Dreams': Fission's Big Comeback

Wall Street Journal

time2 hours ago

  • Wall Street Journal

‘Going Nuclear' and ‘Atomic Dreams': Fission's Big Comeback

Seventy years ago, at the dawn of the nuclear age, atomic energy was viewed as the next great hope of modern civilization. Lewis Strauss, then the chairman of the Atomic Energy Commission, infamously said it could be the key to making energy 'too cheap to meter' and a catalyst for an age of enduring peace. Today, a similar optimism animates the pursuit of nuclear energy. This time, however, the framing is that the peaceful atom is too important to ignore because of its potential to free us of fossil fuels. In 'Going Nuclear: How Atomic Energy Will Save the World,' Tim Gregory sees nuclear energy as the 'only hope' for 'mitigating' climate change because it eliminates 'emissions released as a by-product of burning fossil fuels.' Similarly, in 'Atomic Dreams: The New Nuclear Evangelists and the Fight for the Future of Energy,' Rebecca Tuhus-Dubrow believes 'nuclear advocacy and climate alarm . . . go hand in hand.' These books join dozens of other pro-nuke books published in the past few years.

EMA Launches Review of Tecovirimat Effectiveness for Mpox
EMA Launches Review of Tecovirimat Effectiveness for Mpox

Medscape

time2 hours ago

  • Medscape

EMA Launches Review of Tecovirimat Effectiveness for Mpox

The European Medicines Agency (EMA) has initiated a review of Tecovirimat SIGA, also called TPOXX, a medicine used to treat mpox. This follows emerging clinical trial data suggesting a lack of effectiveness. The mpox virus is an orthopoxvirus, a class that includes the smallpox virus. Tecovirimat SIGA was originally approved in the US to treat smallpox. The EMA and the Medicines and Healthcare products Regulatory Agency in the UK authorized its use in January 2022, at the start of an mpox outbreak in Europe, for the treatment of smallpox, mpox, cowpox, and vaccinia complications following smallpox vaccination, in adults and children weighing at least 13 kg. The drug is an oral medicine that interferes with a protein called VP37 found on the surface of orthopoxviruses, preventing them from reproducing normally and thus slowing the spread of infection. No other treatments are authorized for mpox or cowpox infections, which may in rare cases be fatal. European Cases Linked With Risky Sexual Behaviors Mpox is a zoonotic infection occurring mainly in West and Central Africa, with most cases in Europe before 2022 either imported from countries where mpox is endemic or from contacts with documented epidemiological links to imported cases. The outbreak in the EU and UK has been transmitted between humans mainly through sexual contact. It primarily affects gay, bisexual, or other men who have sex with men and who have multiple sexual partners, participate in group sex, or attend sex-on-premises venues. Transmission occurs primarily within interconnected sexual networks. Symptoms of mpox typically appear 1-3 weeks after infection and include fever, headache, chills, physical weakness, lymph node swelling, back pain, and muscle aches, along with a distinct, fast-spreading papular rash on the skin and mucosal sores in the mouth, nose, throat, or digestive tract that then turn into fluid-filled vesicles. Mild-to-moderate symptoms usually last 2-4 weeks and are followed by full recovery, though some people develop permanent scars. During outbreaks, the case fatality of mpox ranges from 0% to 11%. People who are immunocompromised, including those with HIV infection or AIDS, are at a higher risk for severe disease. Exceptional Circumstances Approval During Outbreak Approval for Tecovirimat SIGA was granted under 'exceptional circumstances' provisions, based only on pharmacodynamic and pharmacokinetic studies, because the disease is rare and sporadic, so human studies were not available. A condition of such authorization is that the company marketing Tecovirimat SIGA is required to provide an annual update on benefits and risks. The EMA's review is a postauthorization procedure that involves a scientific assessment by the agency on behalf of the EU aimed at resolving issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In the case of Tecovirimat SIGA (tecovirimat), the review was initiated at the request of the European Commission. The review follows publication of preliminary results from two clinical trials. In the randomized, placebo-controlled PALM007 trial involving 597 children and adults with laboratory-confirmed clade I mpox in the Democratic Republic of the Congo (DRC), results reported in April in The New England Journal of Medicine showed that the drug did not reduce the duration of mpox lesions (median time to resolution, 7 vs 8 days). The overall mortality among enrollees, regardless of whether or not they received the drug, was 1.6% — much lower than that generally reported in the DRC, but this was attributed to hospitalization and high-quality supportive care within the trial. The other trial, STOMP, involved people from multiple countries with mild-to-moderate laboratory-confirmed or presumptive clade II mpox. Again, the active drug did not demonstrate efficacy in time to skin and mucosal lesion resolution compared with placebo. The EMA said that similar results had recently been obtained from another study, UNITY, which also did not indicate faster skin lesion resolution on tecovirimat compared with placebo. Further analyses from ongoing or recently completed studies are still awaited and will also inform the EMA's final assessment.

EMA OKs Oral Treatment for Postnatal Depression
EMA OKs Oral Treatment for Postnatal Depression

Medscape

time2 hours ago

  • Medscape

EMA OKs Oral Treatment for Postnatal Depression

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on zuranolone (Zurzuvae, Biogen Netherlands BV), the first oral drug to treat postpartum depression in adults. Marketing authorization was granted in recognition of clinical trial results showing a reduction in postpartum depressive symptoms after 2 weeks' treatment. Zuranolone is a neuroactive steroid that enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA). It is thought to exert antidepressant effects by enhancing GABAergic inhibition. In a multicenter, randomized, double-blind, placebo-controlled study, zuranolone at a 50 mg dose was given for 14 days to women who met the Diagnostic and Statistical Manual of Mental Disorders criteria for a major depressive episode of postpartum depression and whose symptoms started in the third trimester or within 4 weeks of delivery. Compared with placebo, the active group demonstrated significantly greater symptom improvement on days 3,15 (the primary endpoint), and 45, using the standard 17-item Hamilton rating scale for depression. The FDA approved the drug in August 2023, at which time it was the first oral treatment for postpartum depression, with previous therapies requiring intravenous dosing. It is available in 20 mg, 25 mg, and 30 mg capsules. The most common side effects are somnolence, dizziness, confusion, trouble walking, and sedation. Patients are advised to avoid alcohol and not to drive, operate machinery, or undertake other dangerous activities until at least 12 hours after taking each dose during the 14-day treatment course. There may also be an increased risk of suicidal thoughts and actions in people 24 years of age and younger. Animal studies have suggested a possible risk of teratogenic effects, so women who may become pregnant are advised to use effective contraception during treatment and for 1 week after the final dose, and to alert their healthcare provider should they become pregnant during treatment. The EMA said that detailed recommendations will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission. Perinatal Mental Healthcare 'in Its Infancy' In Western countries, postpartum depression is estimated to affect between 10% and 15% of women during the first year after birth , with substantial differences in rates depending on socioeconomic factors such as marital status, educational level, social support, spouse care, violence, gestational age, breast feeding, child mortality, financial difficulties, partnership, life stress, smoking, alcohol intake, and living conditions. Common symptoms include feelings of desperation, sadness, anxiety, irritability, and isolation, as well as nausea, changes in sleep and eating habits, decreased libido, crying spells, mental lability, thoughts of hurting oneself and/or the infant, and suicidal ideation. The condition can wreak havoc on women's mental health as well as that of their partners. It can impair the parental relationship, the mother-child bond, and the emotional and cognitive growth of infants, with potential long-term effects. Postnatal depression may occur alongside post-traumatic stress disorder following stressful or traumatic childbirth experiences . Yet a review published in Frontiers in Psychiatry last year suggested that fewer than half of countries in the World Health Organization (WHO) European region had policies specifically on perinatal mental health, leading its authors to conclude that "perinatal mental health care is in its infancy in most WHO European countries."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store